WO2012044728A1 - Oral care compositions with improved flavor - Google Patents

Oral care compositions with improved flavor Download PDF

Info

Publication number
WO2012044728A1
WO2012044728A1 PCT/US2011/053810 US2011053810W WO2012044728A1 WO 2012044728 A1 WO2012044728 A1 WO 2012044728A1 US 2011053810 W US2011053810 W US 2011053810W WO 2012044728 A1 WO2012044728 A1 WO 2012044728A1
Authority
WO
WIPO (PCT)
Prior art keywords
vanillin
oral care
derivatives
stannous
zinc
Prior art date
Application number
PCT/US2011/053810
Other languages
English (en)
French (fr)
Inventor
John Christian Haught
Christine Marie Cahen
Koti Tatachar Sreekishna
Wenzhu Zhao
Yakang Lin
Cathy Renee Schinaman
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to CA2813334A priority Critical patent/CA2813334C/en
Priority to EP11770264.7A priority patent/EP2621462B1/en
Priority to BR112013007295A priority patent/BR112013007295A2/pt
Priority to PL11770264T priority patent/PL2621462T3/pl
Priority to MX2013003645A priority patent/MX349338B/es
Priority to ES11770264T priority patent/ES2787606T3/es
Priority to CN201180047416.3A priority patent/CN103140209B/zh
Priority to AU2011308857A priority patent/AU2011308857B2/en
Publication of WO2012044728A1 publication Critical patent/WO2012044728A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to oral care compositions and methods of improving the taste thereof.
  • TRCs apical membranes of taste receptor cells
  • GPCRs G protein-coupled receptors
  • TRCs are specialized epithelial cells with many neuronal properties including the ability to depolarize and form synapses. TRCs are typically clustered in groups of -100 within taste buds.
  • the apical surface of TRCs which makes contact with the oral cavity, is rich in convoluted microvilli containing GPCRs, ion channels, and other transduction elements.
  • the basolateral aspect of TRCs contains ion channels and synapses with afferent taste nerves.
  • sweeteners are small molecular mass compounds but a few sweet-tasting proteins have been described.
  • Low molecular mass sweeteners and sweet-tasting proteins interact with the same receptor, as shown by recent, direct experiments: at least two of the well-characterized sweet proteins, i.e. brazzein and thaumatin, elicit a response in the human T1R2-T1R3 receptor, similar to that elicited by small molecular mass sweeteners.
  • the sweet taste receptor is a heterodimer of two G protein coupled receptors, T1R2 and T1R3.
  • T1R2:T1R3 taste receptors respond to sweet-tasting compounds such as sugars, high-potency sweeteners, and some D amino acids
  • T1R1 :T1R3 heteromers comprise a umami taste receptor sensitive to L amino acids [12 and 16].
  • Domains of human T1R2 and T1R3 are sufficient to confer sensitivity to some noncaloric sweeteners and sweet-tasting proteins to which rodents are indifferent, but it remains unknown which of these receptor subunits participates in the binding of most sweet stimuli, including sugars.
  • G protein-coupled receptors mediate many other physiological functions, such as endocrine function, exocrine function, heart rate, lipolysis, and carbohydrate metabolism.
  • TRPA1 is a known, nonselective cation channel that belongs to the superfamily of Transient Receptor Potential (TRP) ion channels.
  • TRP Transient Receptor Potential
  • TRPA1 Transient Receptor Potential Ankyrin 1
  • TRPA1 agonists such as citriol, eugenol, thymol, cinnamaldehyde (contained in cinnamon), eugenol, citral, geraniol, eugenol acetate, citral dimethyl acetal, or citral diethyl acetal, and certain flavorings used in oral care compositions typically express pungent, unpleasant tastes in the oral cavity.
  • TRPA1 agonists are desirable in oral care compositions to provide other benefits. Therefore, there is a need to develop oral care compositions that contain materials that can bind to the TRPA1 receptor and yet provide a neutral or positive taste.
  • US Patent Application No. 2008/0124753A1 it was disclosed that a taste profile can be created by dually activating two or more TRP receptors. Although Al could be one of the receptors activated, the compositions of the '753 application required activation of two or more receptors simultaneously to create an acceptable flavor or taste profile and offered no solution for mitigating unpleasant tastes caused by TRPAl agonists.
  • TRPAl ion channel activity by targeting the ion channel TRPM5 and vice versa through the cooperativity mechanism identified therein. More specifically, the US '848 reference disclosed modulating pain, mechanosensation, and taste responses triggered through the ion channels TRPAl and TRPM5.
  • vanillins and vanillin isobutyrate were generally disclosed as one of a series of compounds that gave rise to a sweet odor impression.
  • the disclosed purpose of US '740 was to enhance the sweetness of chalcones via saliva stimulating agents and materials that give an initial burst of sweetness. No means were provided to remedy off-tasting components.
  • US Patent Application No. 2008/0317923A1 disclosed suppression of a bitter, astringent impression in the oral cavity via compositions containing saliva stimulating agents, bitterness- masking aroma substances and/or flavorings, of which vanillin esters were not disclosed.
  • Ethyl vanillin isobutyrate was mentioned as a malodor suppressing agent, but was not disclosed as having an effect on off-tasting or bitter substances.
  • compositions that provide an enhanced perception of an active substance were disclosed.
  • the compositions included an active substance, such as a sweetener or flavor, and a sweetness modifier.
  • the sweetness modifier was disclosed as increasing the perception of sweetness upon consumption.
  • the compositions could be incorporated into various types of edible orally delivered products, such as beverages, food products, confectionary or chewing gum products. Vanillin isobutyrate was disclosed as a potential sweetness modifier.
  • Vanillin isobutyrate was disclosed as a potential sweetness modifier.
  • TRPAl agonists which are esterified methoxy phenol derivatives, uniquely block bitter and off-tasting Al agonists from binding to the Al receptor.
  • vanillin esters and structurally similar compounds act as TRPAl agonists but still result in a neutral or vanilla taste in the oral cavity.
  • Vanillin derivatives, specifically vanillin esters provide a means to balance an oral care composition's taste from bitter and poor tasting to a neutral to positive tasting formula.
  • vanillin esters and structurally similar materials have a relatively strong binding intensity to the TRPAl receptors and can out-compete with other bitter or poor tasting TRPAl agonists found in the oral care composition, resulting in an either neutral or pleasant vanilla taste even when other TRPAl agonists are present in the composition.
  • the vanillin esters "fool" the TRPAl taste receptor so that it does not convey a message to the human body of an unpleasant taste in the oral cavity.
  • the present invention is therefore directed to oral care compositions having improved taste, said composition comprising: a carrier material; from about 0.001 to about 10% , by weight of the composition, of an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and from about 0.0001 to about 1% , by weight of the composition, of a TRPAl agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3- methylpyrazine; phenylmethoxymethylbenzene; (2R)-2-azaniumyl-3-[(2R)-2-azaniumyl-3- oxido-3-o
  • the present invention is further directed to a method for improving taste of an oral care composition, said method comprising the steps of: providing an oral care composition, said composition comprising an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and adding to the oral care composition a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3- enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3-methylpyrazine;
  • a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivative
  • the present invention is further directed to a method for improving the taste of an oral care composition, said method comprising the steps of: providing an oral care composition, said composition a metal salt selected from zinc salts, stannous salts, potassium salts, copper salts, and combinations thereof; and adding to the oral care composition from about 0.001% to about 0.085%, by weight of the composition, of vanillin isobutyrate.
  • the present invention relates to such oral care compositions and methods wherein the TRPA1 agonist is selected from vanillin esters, and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the vanillin ester is selected from vanillin isobutyrate, ethyl vanillin isobutyrate, vanillin acetate, vanillin formate, vanillin propionate, vanillin butyrate, vanillin valerate, vanillin caproate, vanillin myrisate, vanillin laurate, vanillin palmitate, vanillin oleate, vanillin stearate, and combinations thereof.
  • the vanillin ester is selected from vanillin isobutyrate, ethyl vanillin isobutyrate, vanillin acetate, vanillin formate, vanillin propionate, vanillin butyrate, vanillin valerate, vanillin caproate, vanillin myrisate, vanillin laurate, vanillin palmitate, vanillin oleate, vanillin stearate, and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the vanillin ester is selected from vanillin acetate, vanillin formate, vanillin propionate, vanillin butyrate, and combinations thereof.
  • the present invention relates to oral care compositions as described above wherein the vanillin ester is vanillin propionate.
  • the present invention relates to oral care compositions and methods as described above wherein the oral care component is selected from antimicrobial agents, surfactants and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the metal salt is selected from zinc salts, stannous salts, potassium salts, copper salts, and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the stannous salt is selected from stannous fluoride, stannous chloride, stannous iodide, stannous chlorofluoride, stannous actetate, stannous hexafluorozirconate, stannous sulfate, stannous lactate, stannous tartrate, stannous gluconate, stannous citrate, stannous malate, stannous glycinate, stannous pyrophosphate, stannous metaphosphate, stannous oxalate, stannous phosphate, stannous carbonate, and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the zinc salt is selected from zinc fluoride, zinc chloride, zinc iodide, zinc chlorofluoride, zinc actetate, zinc hexafluorozirconate, zinc sulfate, zinc lactate, zinc tartrate, zinc gluconate, zinc citrate, zinc malate, zinc glycinate, zinc pyrophosphate, zinc metaphosphate, zinc oxalate, zinc phosphate, zinc carbonate, and combinations thereof.
  • the zinc salt is selected from zinc fluoride, zinc chloride, zinc iodide, zinc chlorofluoride, zinc actetate, zinc hexafluorozirconate, zinc sulfate, zinc lactate, zinc tartrate, zinc gluconate, zinc citrate, zinc malate, zinc glycinate, zinc pyrophosphate, zinc metaphosphate, zinc oxalate, zinc phosphate, zinc carbonate, and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the potassium salt is selected from potassium nitrate, potassium citrate, potassium oxalate, potassium bicarbonate, potassium acetate, potassium chloride, and combinations thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the composition further comprises a sweetener selected from sucralose, REBIANA, NHDC, acesulfame K, or a combination thereof.
  • a sweetener selected from sucralose, REBIANA, NHDC, acesulfame K, or a combination thereof.
  • the present invention relates to oral care compositions and methods as described above wherein the composition further comprises from about 0.01% to about 30% of an abrasive.
  • the present invention relates to oral care compositions and methods as described above wherein the composition further comprises a TRPA1 enhancer selected from delta-damascone, cis-3-hexenyl cis-3-hexenoate, benzaldehyde dimethyl acetal, carvyl acetate, methyl benzyl butyrate, trans-2-nonen-l-ol, beta-ionol, geraniol, anisyl butyrate, ethyl isoeugenol, alpha-ionone, phenethyl salicylate, 2-phenyl propyl tetrahydrofuran, dihydro- alpha-ionone, thymyl methyl ether, cis-3-hexenyl hexanoate, 2,6,6-trimethyl-l-cyclohexene-l- acetaldehyde, ethyl salicylate, propyl 2,4-decadie
  • the present invention relates to oral care compositions and methods as described above wherein the composition comprises from about 0.01% to about 0.1%, by weight of the composition, of the TRPA1 agonist which is selected from vanillin isobutyrate.
  • compositions include a carrier material; from about 0.001 to about 10% , by weight of the composition, of an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and from about 0.001 to about 1% , by weight of the composition, of a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2- ylmethylsulfanyl)-3-methylpyrazine; phenylmethoxymethylbenzene; (2R)-2-azaniumyl-3-[(2R)-
  • the present invention also relates to methods for improving taste of an oral care composition by adding such TRPA1 agonists to an oral care composition.
  • dentifrice includes paste, gel, or liquid formulations unless otherwise specified.
  • the dentifrice can be in a dual phase form, like a striped paste for example, and can also be used as a regimen.
  • teeth refers to natural teeth as well as artificial teeth or dental prosthesis and is construed to include one tooth or multiple teeth.
  • TRPA1 refers to the transient receptor potential vanilloid receptor 1 which is a ligand-gated, non-selective cation channel preferentially expressed on small-diameter sensory neurons and detects noxious as well as other substances.
  • TRPA1 activator refers to any component which at a concentration of 1 mM gives a calcium flux count of at least 1000 counts above the background level of calcium present in the cell according to the FLIPR method as discussed herein.
  • TRPA1 enhancer refers to any component that boosts the calcium flux activity of a compound that directly activates TRPA1, but does not directly activate TRPA1.
  • oral care composition is meant a product, which in the ordinary course of usage, is not intentionally swallowed for purposes of systemic administration of particular therapeutic agents, but is rather retained in the oral cavity for a time sufficient to contact substantially all of the dental surfaces and/or oral tissues for purposes of oral activity.
  • the oral care composition may be in various forms including toothpaste, dentifrice, tooth gel, subgingival gel, mouthrinse, mousse, foam, mouthspray, lozenge, chewable tablet, chewing gum or denture product,.
  • the oral care composition is in a form selected from toothpaste, dentifrice, tooth gel, mouth rinse or denture product.
  • the oral care composition may also be incorporated onto strips or films for direct application or attachment to oral surfaces.
  • Active and other ingredients useful herein may be categorized or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action or function. However, it is to be understood that the active and other ingredients useful herein can, in some instances, provide more than one cosmetic and/or therapeutic benefit or function or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated function(s) or activities listed.
  • Active and other ingredients useful herein may be categorized or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action or function. However, it is to be understood that the active and other ingredients useful herein can, in some instances, provide more than one cosmetic and/or therapeutic benefit or function or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated function(s) or activities listed.
  • the word “about” means +/- 10 percent.
  • the word “include,” and its variants, are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, compositions, devices, and methods of this invention.
  • Oral care compositions are often made up of a combination of components which can include carrier materials, surfactants, flavors, colorants, sensates, actives, and other additives.
  • Other applicable oral care compositions would be personal health care products (such as cough syrups, cough drops and the like), pharmaceuticals, confectionaries, and foods, (such as chewing gum, soda and the like).
  • compositions of the present invention include from about 5% to about 80%, by weight of the composition, of a carrier material. In one embodiment, the compositions contain from about 10% to about 40%, by weight of the composition, of a carrier material.
  • Examples of materials which can act as a carrier material include water, glycerin, sorbitol, polyethylene glycols having a molecular weight of less than about 50,000, propylene glycol and other edible polyhydric alcohols, ethanol, or combinations thereof.
  • the oral compositions of the present invention comprise from about 0.0001% to about 8%, by weight of the composition, of at least one oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants or a combination thereof.
  • the oral care composition comprises from about 0.01% to about 7%, alternatively from about 0.1% to about 5%, by weight of the composition, of the oral care component.
  • compositions may further include a additional oral care component, discussed below as "optional oral care components".
  • additional oral care components are generally present in an amount of about 0.0001% to about 8%, by weight of the composition.
  • compositions of the present invention may contain from about 0.05% to about 11%, by weight of the oral care composition, of an oral care component selected from metal salts and combinations thereof. In other embodiments, the compositions contain from about 0.5% to about 7% , alternatively from about 1% to about 5%, by weight of the composition, of the metal salt.
  • Metal salts have a wide range of functions from antimicrobial agents to sensitivity agents and/or buffers. In one embodiment, the metal salt comprises a zinc salt, stannous salt, potassium salt, copper salt, or a combination thereof.
  • the zinc salt is selected from zinc fluoride, zinc chloride, zinc iodide, zinc chlorofluoride, zinc actetate, zinc hexafluorozirconate, zinc sulfate, zinc lactate, zinc tartrate, zinc gluconate, zinc citrate, zinc malate, zinc glycinate, zinc pyrophosphate, zinc metaphosphate, zinc oxalate, zinc phosphate, zinc carbonate, and combinations thereof.
  • the zinc salt is selected from zinc chloride, zinc citrate, zinc gluconate, zinc lactate, zinc oxide, and combinations thereof.
  • the potassium salt is selected from potassium nitrate, potassium citrate, potassium oxalate, potassium bicarbonate, potassium acetate, potassium chloride, and combinations thereof.
  • the copper salt is selected from copper fluoride, copper chloride, copper iodide, copper chlorofluoride, copper actetate, copper hexafluorozirconate, copper sulfate, copper lactate, copper tartrate, copper gluconate, copper citrate, copper malate, copper glycinate, copper pyrophosphate, copper metaphosphate, copper oxalate, copper phosphate, copper carbonate, and combinations thereof.
  • the copper salt is selected from copper gluconate, copper acetate, copper glycinate, and combinations thereof.
  • the stannous salt is selected from stannous fluoride, stannous chloride, stannous iodide, stannous chlorofluoride, stannous actetate, stannous
  • the stannous salt is selected from stannous fluoride, stannous chloride, stannous chloride dihydrate, stannous fluoride, stannous lactate, stannous gluconate, stannous sulfate, and combinations thereof.
  • Dentifrices containing stannous salts are described in U.S. Patent 5,004,597 to Majeti et al. Other descriptions of stannous salts are found in U.S. Patent 5,578,293 issued to Prencipe et al. and in U.S. Patent 5,281,410 issued to Lukacovic et al..
  • stannous salts are found in U.S. Patent 5,578,293 issued to Prencipe et al. and in U.S. Patent 5,281,410 issued to Lukacovic et al..
  • other ingredients needed to stabilize the stannous may be included, such as the ingredients described in Majeti et al. and Prencipe et al.
  • Some examples of metal salts which give an off taste include zinc chloride, zinc citrate, copper gluconate, zinc gluconate, or combinations thereof.
  • the oral care composition contains from about 0.1 to about 7%, alternatively from about 1% to about 5% , alternatively from about 1.5% to about 3%, by weight of the oral care composition, of a metal salt selected from stannous salts and combinations thereof. In one embodiment, the oral care composition contains from about 0.01 to about 5 %, alternatively from about 0.05% to about 4%, alternatively from about 0.1% to about 3.0%, by weight of the oral care composition, of a metal salt selected from zinc salts, copper salts, and combinations thereof.
  • compositions of the present invention may contain from about 0.035% or more, alternatively from about 0.1% to about 1.5%, alternatively from about 0.045% to about 1.0%, alternatively from about 0.05% to about 0.10%, by weight of the oral care composition, of an oral care component selected from antimicrobial agents.
  • an antimicrobial agent useful herein is a quaternary ammonium compound.
  • Those useful herein include, for example, those in which one or two of the substitutes on the quaternary nitrogen has a carbon chain length (typically alkyl group) from about 8 to about 20, typically from about 10 to about 18 carbon atoms while the remaining substitutes (typically alkyl or benzyl group) have a lower number of carbon atoms, such as from about 1 to about 7 carbon atoms, typically methyl or ethyl groups.
  • Other compounds include bis[4-(R-amino)-l-pyridinium] alkanes as disclosed in U.S. Patent No. 4,206,215, Jun. 3, 1980, to Bailey.
  • Other quaternary ammonium compounds include the pyridinium compounds.
  • Examples of pyridinium quaternary ammonium compounds include cetylpyridinium and tetradecylpyridinium halide salts (i.e., chloride, bromide, fluoride and iodide).
  • the oral care compositions of the present invention may also include other antimicrobial agents including non-cationic antimicrobial agents such as halogenated diphenyl ethers, phenolic compounds including phenol and its homologs, mono and poly-alkyl and aromatic halophenols, resorcinol and its derivatives, xylitol, bisphenolic compounds and halogenated salicylanilides, benzoic esters, and halogenated carbanilides.
  • Also useful antimicrobials are enzymes, including endoglycosidase, papain, dextranase, mutanase, and combinations thereof. Such agents are disclosed in U.S. Patent 2,946,725, Jul. 26, 1960, to Norris et al.
  • antimicrobial agents examples of some which provide an unwanted taste include, for example, chlorhexidine, triclosan, and thymol.
  • the unwanted tastes often associated with these types of antimicrobial agents include bitter, dirty, earthy, sour, and/or astringent.
  • compositions of the present invention may contain from about 0.01% to about 4.0%, by weight of the composition, of an oral care component selected from bad breath reduction agents. These agents generally work to reduce breath malodor.
  • bad breath reduction agents include copper salts and carbonyl compounds such as ascorbic acid [3-oxo-L-gulofuranolactone]; cis-jasmone [3-methyl-2-(2-pentenyl-2- cyclopentenone] ; 2,5-dimethyl-4-hydroxy-3(2H)-furanone; 5-ethyl-3-hydroxy-4-methyl-2(5H)- furanone; vanillin [4-hydroxy-3-methoxybenzaldehyde]; ethyl vanillin; anisaldehyde [4- methoxybenzaldehyde] ; 3,4-methylenedioxybenzaldehyde; 3,4-dimethoxybenzaldehyde; 4- hydroxybenzaldehyde; 2-methoxybenzaldehyde; benzaldehyde; cinnamaldehyde [3-phenyl-2- propenal]; hexyl cinnamaldehyde;
  • bad breath reduction agents work as "traps" by reacting with the thiol or sulfide and forming products with less odor impact.
  • bad breath reduction agents an example of one which provide an unwanted taste within an oral care composition include, for example, anisaldehyde.
  • the unwanted tastes often associated with these types of bad breath reduction agents include chemical, plastic, bitter, and/or sour.
  • compositions of the present invention may contain from about 0.01% to about 30%, alternatively from about 0.1% to about 10%, alternatively from about 0.5% to about 5%, by weight of the composition, of an oral care component selected from bleaching agents.
  • Bleaching agents are generally agents which whiten teeth.
  • bleaching agents include peroxides, perborates, percarbonates, peroxyacids, persulfates, and combinations thereof.
  • Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, sodium peroxide, zinc peroxide, or combinations thereof.
  • One example of a percarbonate is sodium percarbonate.
  • An example of a persulfate includes oxones.
  • the following amounts represent the amount of peroxide raw material, although the peroxide source may contain ingredients other than the peroxide raw material.
  • the peroxide source could be a solution a peroxide raw material and a carrier material.
  • examples of some which provide an unwanted taste within an oral care composition include, for example, peroxide and percarbonate. The unwanted tastes often associated with these bleaching agents include dirty, chemical, and/or sour.
  • compositions of the present invention may contain from about 0.1% to about 15%, alternatively from about 0.5% to about 5%, by weight of the composition, of an oral care component selected from surfactants.
  • the surfactant may be selected from anionic, nonionic, amphoteric, zwitterionic, cationic, or combinations thereof.
  • Anionic surfactants useful herein include, for example, the water-soluble salts of alkyl sulfates having from 8 to 20 carbon atoms in the alkyl radical (e.g., sodium alkyl sulfate) and the water-soluble salts of sulfonated monoglycerides of fatty acids having from 8 to 20 carbon atoms.
  • Sodium lauryl sulfate (SLS) and sodium coconut monoglyceride sulfonates are examples of anionic surfactants of this type.
  • anionic surfactants include sarcosinates, such as sodium lauroyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecyl benzenesulfonate. Combinations of anionic surfactants can also be employed. Many suitable anionic surfactants are disclosed by Agricola et al., U.S. Patent 3,959,458. In varying embodiments, the present compositions comprise an anionic surfactant at a level of from about 0.025% to about 9%, from about 0.05% to about 5%, or from about 0.1% to about 1%.
  • alkyl phosphates Another class of anionic surfactants useful here are alkyl phosphates.
  • the surface active organophosphate agents have a strong affinity for enamel surface and have sufficient surface binding propensity to desorb pellicle proteins and remain affixed to enamel surfaces.
  • Suitable examples of organophosphate compounds include mono-, di- or triesters represented by the general structure below wherein Zl, Z2, or Z3 may be identical or different, at least one being an organic moiety, in one embodiment selected from linear or branched, alkyl or alkenyl group of from 1 to 22 carbon atoms, optionally substituted by one or more phosphate groups; alkoxylated alkyl or alkenyl, (poly)saccharide, polyol or polyether group.
  • alkyl or alkenyl phosphate esters represented by the following structure:
  • Rl represents a linear or branched, alkyl or alkenyl group of from 6 to 22 carbon atoms, optionally substituted by one or more phosphate groups; n and m, are individually and separately, 2 to 4, and a and b, individually and separately, are 0 to 20; Z2 and Z3 may be identical or different, each represents hydrogen, alkali metal, ammonium, protonated alkyl amine or protonated functional alkyl amine such as an alkanolamine, or a Rl— (OCnH2n)a(OCmH2m)b— group.
  • alkyl and alkyl (poly)alkoxy phosphates such as lauryl phosphate; PPG5 ceteareth-10 phosphate; Laureth-1 phosphate; Laureth-3 phosphate; Laureth-9 phosphate; Trilaureth-4 phosphate; C12-18 PEG 9 phosphate; Sodium dilaureth-10 phosphate.
  • the alkyl phosphate is polymeric.
  • polymeric alkyl phosphates include those containing repeating alkoxy groups as the polymeric portion, in particular 3 or more ethoxy, propoxy isopropoxy or butoxy groups.
  • Additional suitable polymeric organophosphate agents include dextran phosphate, polyglucoside phosphate, alkyl polyglucoside phosphate, polyglyceryl phosphate, alkyl polyglyceryl phosphate, polyether phosphates and alkoxylated polyol phosphates.
  • PEG phosphate PPG phosphate, alkyl PPG phosphate, PEG/PPG phosphate, alkyl PEG/PPG phosphate, PEG/PPG/PEG phosphate, dipropylene glycol phosphate, PEG glyceryl phosphate, PBG (polybutylene glycol) phosphate, PEG cyclodextrin phosphate, PEG sorbitan phosphate, PEG alkyl sorbitan phosphate, and PEG methyl glucoside phosphate.
  • Suitable non- polymeric phosphates include alkyl mono glyceride phosphate, alkyl sorbitan phosphate, alkyl methyl glucoside phosphate, alkyl sucrose phosphates.
  • Another suitable surfactant is one selected from sarcosinate surfactants, isethionate surfactants and taurate surfactants.
  • an alkali metal or ammonium salts of these surfactants are used. Examples of those sodium and potassium salts include following: lauroyl sarcosinate, myristoyl sarcosinate, palmitoyl sarcosinate, stearoyl sarcosinate and oleoyl sarcosinate, or combinations thereof.
  • anionic surfactants examples of some which provide an unwanted taste within an oral care composition include, for example, SLS, lauroyl sarcosinate, and/or fatty alcohols or acids associated with natural based surfactants. The unwanted tastes often associated with these surfactants are soapy, chemical, and/or artificial.
  • Zwitterionic or amphoteric surfactants useful in oral care compositions include derivatives of aliphatic quaternary ammonium, phosphonium, and sulfonium compounds, in which the aliphatic radicals can be straight chain or branched, and one of the aliphatic substituents contains from about 8 to 18 carbon atoms and one contains an anionic water- solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate or phosphonate.
  • Suitable betaine surfactants are disclosed in U.S. Patent 5,180,577 to Polefka et al.
  • Typical alkyl dimethyl betaines include decyl betaine or 2-(N-decyl-N,N-dimethylammonio) acetate, coco betaine or 2- (N-coco-N, N-dimethyl ammonio) acetate, myristyl betaine, palmityl betaine, lauryl betaine, cetyl betaine, cetyl betaine, stearyl betaine, etc.
  • the amidobetaines are exemplified by cocoamidoethyl betaine, cocoamidopropyl betaine (CADB), and lauramidopropyl betaine.
  • examples of some which provide an unwanted taste within an oral care composition include, for example, cocoamidopropyl betaine and lauryl betaine.
  • the unwanted tastes often associated with these types of surfactants are soapy and chemical.
  • These surfactants are generally included in an oral care composition in a range of about 0.5% to about 5%.
  • Cationic surfactants useful in the present invention include, for example, derivatives of quaternary ammonium compounds having one long alkyl chain containing from about 8 to 18 carbon atoms such as lauryl trimethylammonium chloride; cetyl pyridinium chloride; cetyl trimethylammonium bromide; coconut alkyltrimethylammonium nitrite; cetyl pyridinium fluoride or combinations thereof. Additional quaternary ammonium fluorides having detergent properties are described in U.S. Patent 3,535,421 to Briner et al. Of these surfactants, examples of some which provide an unwanted taste within an oral care composition include, for example, cetyl pyridinium chloride or chlorhexidine.
  • Nonionic surfactants that can be used in the compositions of the present invention include, for example, compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkylaromatic in nature.
  • nonionic surfactants include the Pluronics® which are poloxamers, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine, ethylene oxide condensates of aliphatic alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides and combinations of such materials.
  • compositions of the present invention comprise from about 0.0001% to about 1%, alternatively from about 0.0001% to about 0.4%, still alternatively from about 0.001% to about 0.3%, by weight of the composition, of a TRPA1 agonist selected from vanillin esters and structurally similar compounds.
  • a TRPA1 agonist selected from vanillin esters and structurally similar compounds.
  • vanillin esters although suitable off-taste mitigators, may not be structurally suitable for all formulations.
  • ester hydrolysis may occur.
  • Some of the linear derivatives, where they have unprotected esters, may undergo hydrolysis. Therefore, one of the structural derivatives would be chosen to suit the formula environment.
  • vanillin esters and structurally similar compounds useful herein include: vanillin esters; benzoate esters; hydroxybenzoate derivative; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3- methylpyrazine; phenylmethoxymethylbenzene; (2R)-2-azaniumyl-3-[(2R)-2-azaniumyl-3- oxido-3-oxopropyl]disulfanylpropanoate; (3E)-2-hydroxy-4,8-dimethylnona-3,7-dienal; (2R)-2- azaniumyl-3-[(2S)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate
  • the composition comprises from about 0.0001% to about 1%, alternatively from about 0.0001 % to about 0.4 %, by weight of the composition, of the TRPA1 agonist which is selected from vanillin esters.
  • the TRPA1 agonist which is selected from vanillin esters.
  • levels are lower than that typically utilized to impart a sweet flavor but are high enough to act as the TRPAl agonist.
  • vanillin esters One benefit to using lower levels of vanillin esters is that the molecule will not interfere with the character of an added flavor, such as peppermint or spearmint.
  • Vanillin esters are identified as esterified vanillin according to the structure below:
  • Rl linear or branched or cyclic, CI to C22 alkyl, alkene, alkyne.
  • R2 hydrogen, linear or branched, CI to C6 alkyl, alkene, alkyne.
  • the preferred esters are C1-C6 linear or branched alkyl or alkene chains. The most preferred are acetate, formate, propionate, and butyrate esters.
  • vanillin esters examples include: vanillin isobutyrate, ethyl vanillin isobutyrate, vanillin acetate, vanillin formate, vanillin propionate, vanillin butyrate, vanillin valerate, vanillin caproate, vanillin myrisate, vanillin laurate, vanillin palmitate, vanillin oleate, vanillin stearate, and combinations thereof.
  • the vanillin ester is selected from vanillin acetate, vanillin formate, vanillin propionate, vanillin butyrate, and combinations thereof.
  • the composition comprises from about 0.001% to about 0.085%, alternatively fraom about 0.002% to about 0.0o7%, by weight of the composition of the TRPAl agonist selected from vanillin isobutyrate.
  • the vanillin ester is vanillin propionate.
  • the composition comprises from about 0.0001% to about 1%, alternatively from about 0.0001 % to about 0.4 %, by weight of the composition, of the TRPAl agonist which is selected from compounds structurally similar to vanillin esters.
  • Such compounds may be identified using one of two methods; Daylight fingerprint based similarity searching; and molecular shape based similarity searching. Both algorithms are implemented in the Chemistry Development Kit (CDK), an open-source java library.
  • CDK Chemistry Development Kit
  • fingerprint based similarity search vanillin isobutyrate and each candidate compound is represented by a fingerprint or a bit string (a sequence of 0 and 1 digit), which is derived from enumeration of all linear substructures of length N in each compound.
  • T Tanimoto coefficient
  • Structurally similar compounds useful herein include those shown below in Table I: Table I - Structurally Similar Compounds
  • compositions of the present invention may further comprise from about 0.001% to about 3.0%, alternatively from about 0.005% to about 1.0%, by weight of the composition, of a TRPA1 enhancer selected from delta-damascone, cis-3-hexenyl cis-3-hexenoate, benzaldehyde dimethyl acetal, carvyl acetate, methyl benzyl butyrate, trans-2-nonen-l-ol, beta-ionol, geraniol, anisyl butyrate, ethyl isoeugenol, alpha-ionone, phenethyl salicylate, 2-phenyl propyl tetrahydrofuran, dihydro-alpha-ionone, thymyl methyl ether, cis-3-hexenyl hexanoate, 2,6,6- trimethyl-l-cyclohexene-l-acetaldehyde, ethyl
  • compositions of the present invention may also contain from about 0.0001% to about 8%, alternatively from about 0.001% to about 5%, by weight of the composition, of an optional oral care component.
  • Optional oral care components include flavors, anti-tartar agents, colorants, sensates, sweeteners, abrasive polishing materials, anticaries agents, and combinations thereof.
  • Another component which can be part of an oral care composition includes flavors.
  • Flavors are generally present in an amount of about 0.4 % to about 3% by weight of the oral care composition.
  • examples of some flavors and flavor components used in oral care compositions are mint oils, wintergreen, clove bud oil, cassia, sage, parsley oil, marjoram, lemon, orange, propenyl guaethol, heliotropine, 4-cis-heptenal, diacetyl, methyl-p-tert-butyl phenyl acetate, methyl salicylate, ethyl salicylate, 1-menthyl acetate, oxanone, a-irisone, methyl cinnamate, ethyl cinnamate, butyl cinnamate, ethyl butyrate, ethyl acetate, methyl anthranilate, iso-amyl acetate, iso-amyl butyrate, allyl caproate, eugenol, eucaly
  • suitable flavoring ingredients are chemicals with structural features and functional groups that are less prone to redox reactions. These include derivatives of flavor chemicals that are saturated or contain stable aromatic rings or ester groups. Of these flavors, examples of some which provide an unwanted taste include, for example, citral, geranial, eucalyptol, and eugenol. The unwanted tastes often associated with these types of flavors are sourness, chemical, bitter, pungent, and/or astringent.
  • anti-tartar agents Another component which can be part of an oral care composition includes anti-tartar agents.
  • an antitartar agent is a pyrophosphate salt as a source of pyrophosphate ion.
  • the pyrophosphate salts useful in the present compositions include, for example, the mono-, di- and tetraalkali metal pyrophosphate salts and combinations thereof.
  • the pyrophosphate salt may be present in one of three ways: predominately dissolved, predominately undissolved, or a combination of dissolved and undissolved pyrophosphate.
  • the amount of pyrophosphate salt useful in making these compositions is any tartar control effective amount. In varying embodiments, the amount of pyrophosphate salt is from about 1.5% to about 15%, from about 2% to about 10%, or about 3% to about 8%, by weight of the oral care composition.
  • Another component which can be part of an oral care composition includes colorants.
  • Colorants are generally present in an amount of about 0.001% to about 0.5%, by weight of the oral care composition.
  • examples of some colorants used in oral care compositions include D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red No. 40, D&C Red No. 33 and combinations thereof.
  • the composition comprises from about 0.0001 % to about 0.1%, alternatively from about 0.001% to about 0.01%, by weight of the oral care composition, of a colorant.
  • an example of a colorant which provides an unwanted taste includes, for example, D&C Red No. 33.
  • the unwanted tastes often associated with this colorant are metallic, sharp, and/or chemical.
  • Sensate molecules such as cooling, warming, and tingling agents are useful to deliver signals to the consumer. Sensates are generally present in an amount of from about 0.001% to about 0.8%, by weight of the oral care composition.
  • the most well-known cooling sensate compound is menthol, particularly 1-menthol, which is found naturally in peppermint oil.
  • Other isomers of menthol (neomenthol, isomenthol and neoisomenthol) have somewhat similar, but not identical odor and taste, i.e., having disagreeable notes described as earthy, camphor, musty, etc.
  • the biggest difference among the isomers is in their cooling potency.
  • L-menthol provides the most potent cooling, i.e., having the lowest cooling threshold of about 800 ppb, i.e., the concentration level where the cooling effect could be clearly recognized. At this level, there is no cooling effect for the other isomers.
  • menthol particularly l-menthol, which is found naturally in peppermint oil, notably of Mentha arvensis L and Mentha viridis L.
  • isomers of menthol the 1-isomer occurs most widely in nature and is typically what is referred by the name menthol having coolant properties.
  • L-menthol has the characteristic peppermint odor, has a clean fresh taste and exerts a cooling sensation when applied to the skin and mucosal surfaces.
  • Other isomers of menthol (neomenthol, isomenthol and neoisomenthol) have somewhat similar, but not identical odor and taste, i.e., some having disagreeable notes described as earthy, camphor, musty.
  • L-menthol provides the most potent cooling, i.e., having the lowest cooling threshold of about 800 ppb, i.e., the concentration where the cooling effect could be clearly recognized. At this level, there is no cooling effect for the other isomers.
  • d- neomenthol is reported to have a cooling threshold of about 25,000 ppb and 1-neomenthol about 3,000 ppb.
  • menthane carboxy esters examples include WS-4 and WS-30.
  • An example of a synthetic carboxamide coolant that is structurally unrelated to menthol is N,2,3-trimethyl-2- isopropylbutanamide, known as "WS-23".
  • TK-10 3-(l-menthoxy)-propane-l,2-diol known as TK-10, isopulegol (under the tradename Coolact P) and p-menthane-3,8-diol (under the tradename Coolact 38D) all available from Takasago
  • MGA menthone glycerol acetal
  • MGA menthyl esters
  • Frescolat® supplied by
  • TK-10 is described in U.S. Pat. No. 4,459,425 to Amano et al.
  • Other alcohol and ether derivatives of menthol are described e.g., in GB 1,315,626 and in U.S. Pat. Nos. 4,029,759; 5,608,119; and 6,956,139.
  • WS-3 and other carboxamide cooling agents are described for example in U.S. Pat. Nos. 4,136,163; 4,150,052; 4,153,679; 4,157,384; 4,178,459 and 4,230,688.
  • N-substituted p-menthane carboxamides are described in WO 2005/049553A1 including N-(4-cyanomethylphenyl)-p-menthanecarboxamide, N-(4-sulfamoylphenyl)-p- menthanecarboxamide, N-(4-cyanophenyl)p-menthanecarboxamide, N-(4-acetylphenyl)-p- menthanecarboxamide, N-(4-hydroxymethylphenyl)-p-menthanecarboxamide and N-(3-hydroxy-
  • N-substituted p-menthanecarboxamides include amino acid derivatives such as those disclosed in WO 2006/103401 and in U.S. Pat. Nos. 4,136,163; 4,178,459 and 7,189,760 such as N-((5-methyl-2-(l- methylethyl)cyclohexyl)carbonyl) glycine ethyl ester and N-((5-methyl-2-(l- methylethyl)cyclohexyl)carbonyl)alanine ethyl ester.
  • Menthyl esters including those of amino acids such as glycine and alanine are disclosed e.g., in EP 310,299 and in U.S. Pat. Nos.
  • Ketal derivatives are described, e.g., in U.S. Pat. Nos. 5,266,592; 5,977,166 and 5,451,404. Additional agents that are structurally unrelated to menthol but have been reported to have a similar physiological cooling effect include alpha-keto enamine derivatives described in U.S. Pat. No.
  • 6,592,884 including 3-methyl-2-(l-pyrrolidinyl)-2-cyclopenten-l-one (3-MPC), 5- methyl-2-(l-pyrrolidinyl)-2-cyclopenten-l-one (5-MPC), and 2,5-dimethyl-4-(l-pyrrolidinyl)- 3(2H)-furanone (DMPF); icilin (also known as AG-3-5, chemical name l-[2-hydroxyphenyl]-4- [2-nitrophenyl]-l,2,3,6-tetrahydropyrimidine-2-one) described in Wei et al., J. Pharm.
  • warming sensates include ethanol; capsicum; nicotinate esters, such as benzyl nicotinate; polyhydric alcohols; capsicum powder; a capsicum tincture; capsicum extract; capsaicin; homocapsaicin; homodihydrocapsaicin; nonanoyl vanillyl amide; nonanoic acid vanillyl ether; vanillyl alcohol alkyl ether derivatives such as vanillyl ethyl ether, vanillyl butyl ether, vanillyl pentyl ether, and vanillyl hexyl ether; isovanillyl alcohol alkyl ethers; ethylvanillyl alcohol alkyl ethers; veratryl alcohol derivatives; substituted benzyl alcohol derivatives;
  • Warming sensates are generally included in an oral care composition at a level of about 0.05% to about 2%, by weight of the composition.
  • compositions of the present invention comprise vanillyl butyl ether.
  • a composition comprises vanillin isobutyrate in an amount from about 0.0001% to about 0.02%, by weight of the composition, and vanillyl butyl ether in an amount from about 0.0001% to about 0.02%, by weight of the composition.
  • vanillin isobutyrate and vanillyl butyl ether are in the composition in an about 1: 1 ratio.
  • Tingling sensates include, jambu Oleoresin, Zanthoxylum peperitum, saanshool-I, saanshool II, sanshoamide, piperine, piperidine, eugenol, spilanthol, 4-(l- methoxymethyl)-2-phenyl- 1,3-dioxolane, or combinations thereof.
  • Tingling sensates are generally included in an oral care composition at a level of about 0.0005% to about 1 %, by weight of the composition.
  • examples of some which provide an unwanted taste within an oral care composition include, for example, jambu, saanshool, and/or eugenol.
  • the unwanted taste(s) often associated with these tingling sensates include a peppery, bitter, and/or metallic taste.
  • sweeteners include those selected from saccharin, chloro-sucrose (sucralose), steviolglycosides, rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, dulcoside B, rubusoside, stevia, stevioside, acesulfame K, xylitol, neohesperidine DC, alitame, aspartame, neotame, alitame, thaumatin, cyclamate, glycyrrhizin, mogroside IV, mogroside V, Luo Han Guo sweetener, siamenoside, monatin and its salts (monatin SS, RR, RS, SR), curculin, monellin, mabinlin, bra
  • REBIANA is a steviolglycoside from Cargill, which is an extract from the leaves of the Stevia rebaudiana plant (hereinafter referred to as "REBIANA"). This is a crystalline diterpene glycoside, about 300x sweeter than sucrose.
  • suitable stevioglycosides which may be combined include rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, dulcoside A, dulcoside B, rubusoside, stevioside, or
  • the combination of high-potency sweeteners comprises rebaudioside A in combination with rebaudioside B, rebaudioside C, rebaudioside F, rebaudioside F, stevioside, steviolbioside, dulcoside A.
  • Sweeteners are generally included in an oral care composition at a level of about 0.0005% to about 2 %.
  • the sweetener is selected from , REBIANA, NHDC, acesulfame K, and combinations thereof. Additionally, a flavor enhancer such as glucono-5-lactone can be added to the sweetener composition.
  • compositions of the present invention may comprise from about 6% to about 70%, alternatively from about 10% to about 50%, by weight of the composition, of an abrasive polishing material.
  • An abrasive polishing material may also be included in the oral compositions.
  • the abrasive polishing material contemplated for use in the compositions of the present invention can be any material that does not excessively abrade dentin.
  • Typical abrasive polishing materials include silicas including gels and precipitates; aluminas; phosphates including orthophosphates, polymetaphosphates, and pyrophosphates; and mixtures thereof.
  • abrasives include dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate, insoluble sodium polymetaphosphate, rice hull silica, hydrated alumina, beta calcium pyrophosphate, calcium carbonate, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and others such as disclosed by Cooley et al in U.S. Patent 3,070,510, issued Dec. 25, 1962. Mixtures of abrasives may also be used. If the oral composition or particular phase comprises a polyphosphate having an average chain length of about 4 or more, calcium containing abrasives and alumina are not preferred abrasives. The most preferred abrasive is silica.
  • Silica dental abrasives of various types are preferred because of their unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentine.
  • the silica abrasive polishing materials herein, as well as other abrasives generally have an average particle size ranging between about 0.1 to about 30 microns, and preferably from about 5 to about 15 microns.
  • the abrasive can be precipitated silica or silica gels such as the silica xerogels described in Pader et al., U.S. Patent 3,538,230, issued Mar. 2, 1970, and DiGiulio, U.S. Patent 3,862,307, issued Jan. 21, 1975.
  • silica xerogels marketed under the trade name "Syloid” by the W.R. Grace & Company, Davison Chemical Division.
  • precipitated silica materials such as those marketed by the J. M. Huber Corporation under the trade name, "Zeodent", particularly the silica carrying the designation "Zeodent 119.”
  • the types of silica dental abrasives useful in the toothpastes of the present invention are described in more detail in Wason, U.S. Patent 4,340,583, issued July 29, 1982. Silica abrasives are also described in Rice, U.S. Patents 5,589,160; 5,603,920; 5,651,958; 5,658,553; and 5,716,601.
  • Another component which can be part of an oral care composition includes anticaries agents.
  • Anticaries agents are generally used in an amount of about 0.01 % to about 3.0 %, by weight of the composition. It is common to have a fluoride compound present in dentifrices and other oral compositions in an amount sufficient to give a fluoride ion concentration in the composition of from about 0.0025% to about 5.0% by weight to provide anticaries effectiveness. In one embodiment, the fluoride concentration is from about 0.005% to about 2.0% by weight.
  • fluoride ion-yielding materials can be employed as sources of soluble fluoride in the present compositions and methods. Examples of suitable fluoride ion- yielding materials are found in U.S. Patent No.
  • Representative fluoride ion sources include: stannous fluoride, sodium fluoride, potassium fluoride, amine fluoride, sodium monofluorophosphate, indium fluoride, amine fluorides such as Olaflur, and many others.
  • the anticaries agent comprises stannous fluoride in an amount of about 0.454 %. In another embodiment, the anticaries agent comprises sodium fluoride in an amount of about 0.243 %.
  • the present invention also relates to methods of improving the taste of an oral care composition by the inclusion of from about 0.0001% to about 1%, by weight of the oral care composition, of a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivative; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3-methylpyrazine; phenylmethoxymethylbenzene; (2R)-2- azaniumyl-3-[(2R)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3E)-2-hydroxy-4,8- dimethylnona-3,7-dienal; (2R)-2-azaniumyl-3-[(2S)
  • Such methods include the step of providing an oral care composition comprising an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof.
  • an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof.
  • such oral care components are known to create off-tastes in oral care compositions.
  • Such off-tastes may include metallic; soapy; earthy; antibacterial off-tastes; and salty.
  • the oral care compositions and optional components thereof are discussed in more detail above.
  • Such methods further include the step of adding to the oral care composition the TRPA1 agonist.
  • the method comprises providing an oral care composition comprising a zinc salt, stannous salt, a potassium salt, copper salt, or a combination thereof; and adding to the oral care composition from about 0.001 % to about 0.085 % of vanillin isobutyrate, by weight of the oral care composition.
  • TRPA1 Agonists In order to select TRPAl agonists that would be preferred for reducing off-tasting chemical components found in oral care compositions, calcium flux receptor activity on the TRPAl was utilized as the criteria for selection of actives.
  • allyl isothiocyanate as the TRPAl positive control, molecules that directly activated the TRPAl receptor were screened in dimethylsulfoxide (DMSO). Pure molecules of each material were dissolved in DMSO at a concentration of 100 micormolar and then added to an HEK cell line containing the TRPAl receptor. If they are TRPAl agonists, they will cause a calcium flux in the cell which fluoresces and may then be measured using a FLIPR machine. The results of such measurement are calculated as calcium counts which are then converted to the figures shown in Table II as a percentage of the control calcium count. Any preincubation figure provided that is higher than 100 means that the material is more active than the control.
  • Rhodinol 70 Spec 59508 141-25-3 87.57 -9.13
  • Cocamidopropyl Betaine (30%) 3.3 3.3 3.3 3.3 3.3 3.3 3.3 Xanthan gum 0.2 0.2 0.2 0.2 0.2 0.2 0.2
  • Carbomer 956 0.3 0.3 0.3 0.3 0.3 0.3 0.3
  • Titanium Dioxide Anatase 0.2 0.2 0.2 0.2 0.2 0.2 0.2
  • Vanillin 20665- 118% Great reduction in bitter Isobutyrate 85-4 taste with no aftertaste.
  • Oral care compositions according to the present invention are made by conventional methods and are exemplified below as formulations Ila through Hi.
  • Carbomer 956 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
  • Poloxamer 407 1.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2
  • Titanium Dioxide 0.5 1.0 0.25 0.3 0.3 0.2 0.2
  • Dentifrices according to the present invention are made using conventional methods and are shown below as Example formulations IIA - IIIK with amounts in weight %.
  • Flavor 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
  • Flavor comprises about 31.3% menthol supplying ppm menthol.
  • Mouth rinse compositions according to the present invention are made using conventional methods and are shown below as Example formulations IVA through IVC with amounts of components in weight %.
  • Peroxide-containing mouth rinse compositions according to the present invention are shown below as Example formulations VA through VF, with amounts of components in weight %. These compositions are made using conventional methods.
  • the mouth rinse compositions provide a pleasant high-impact minty taste during use and noticeable long-lasting fresh breath.
  • Tartar control dentifrice compositions according to the present invention are made using conventional methods and are shown below as Exmaples VIA through VIE with amounts in weight %.
  • Poloxamer 407 NF 1.00 0.20 Vanillin Isobutyrate 0.06 0.03 0.08 0.02 0.06
  • a dentifrice composition formulated with 0.01% vanillin isobutyrate and 0.01% VBE, by weight of the composition was used by a panel of consumers.
  • sample B the same consumers tested a similar formula as sample A that had 0.005% G-180 instead of the vanillin isobutyrate and VBE (sample B), and a similar formula to sample A comprising 0.01% vanillin isobutyrate, 0.01% VBE, and 0.005% G-180 (sample C), in addition to commercially available Crest Complete Extra Fresh (sample D), and commercially available Odol med 3 Original (sample E).
  • Example E commercially available Crest Complete Extra Fresh
  • sample A formulated with vanillin isobutyrate and VBE can drive consumer freshness perception.
  • the zinc in formulas A-C was able to be best masked by the vanillin isobutyrate and VBE combination in formulas A and C, as indicated by the higher refreshing taste ratings (66 for A and 67 for C, compared to 52 for B).
  • Carbomer 956 0.000 0.000 0.000 0.400
  • Disodium pyrophosphate 0.000 0.000 0.000 1.700
  • VBE Vanillyl Butyl Ether

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
PCT/US2011/053810 2010-10-01 2011-09-29 Oral care compositions with improved flavor WO2012044728A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2813334A CA2813334C (en) 2010-10-01 2011-09-29 Oral care compositions with improved flavor
EP11770264.7A EP2621462B1 (en) 2010-10-01 2011-09-29 Oral care compositions with improved flavor
BR112013007295A BR112013007295A2 (pt) 2010-10-01 2011-09-29 composições para tratamento bucal com sabor aprimorado
PL11770264T PL2621462T3 (pl) 2010-10-01 2011-09-29 Kompozycje do higieny jamy ustnej o ulepszonym aromacie
MX2013003645A MX349338B (es) 2010-10-01 2011-09-29 Composiciones para el cuidado bucal con sabor mejorado.
ES11770264T ES2787606T3 (es) 2010-10-01 2011-09-29 Composiciones para el cuidado bucal con mejor sabor
CN201180047416.3A CN103140209B (zh) 2010-10-01 2011-09-29 具有改善的风味的口腔护理组合物
AU2011308857A AU2011308857B2 (en) 2010-10-01 2011-09-29 Oral care compositions with improved flavor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38875210P 2010-10-01 2010-10-01
US61/388,752 2010-10-01

Publications (1)

Publication Number Publication Date
WO2012044728A1 true WO2012044728A1 (en) 2012-04-05

Family

ID=44801183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053810 WO2012044728A1 (en) 2010-10-01 2011-09-29 Oral care compositions with improved flavor

Country Status (10)

Country Link
US (1) US9937115B2 (en_2)
EP (1) EP2621462B1 (en_2)
CN (1) CN103140209B (en_2)
AU (1) AU2011308857B2 (en_2)
BR (1) BR112013007295A2 (en_2)
CA (1) CA2813334C (en_2)
ES (1) ES2787606T3 (en_2)
MX (1) MX349338B (en_2)
PL (1) PL2621462T3 (en_2)
WO (1) WO2012044728A1 (en_2)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015134754A (ja) * 2013-12-19 2015-07-27 花王株式会社 香料前駆体
JP2017008446A (ja) * 2015-06-23 2017-01-12 花王株式会社 液体柔軟剤組成物
WO2017116445A1 (en) 2015-12-30 2017-07-06 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
KR20190107718A (ko) * 2017-03-16 2019-09-20 가부시키가이샤 지씨 치아 표백용 조성물
US10980719B2 (en) 2015-12-30 2021-04-20 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130315843A1 (en) * 2012-05-25 2013-11-28 The Procter & Gamble Company Composition for reduction of trpa1 and trpv1 sensations
US10182584B2 (en) * 2012-12-12 2019-01-22 Symrise Ag Cooling preparations
WO2014143017A1 (en) * 2013-03-15 2014-09-18 Colgate-Palmolive Company Oral care composition and processes for preparing same
WO2016025414A1 (en) * 2014-08-15 2016-02-18 The Procter & Gamble Company Oral care compositions and regimens
BR112017010941B1 (pt) 2014-12-18 2021-07-27 Colgate-Palmolive Company Composição de higiene bucal com elevado teor de água e micro robustez e método para limpeza da superfície de um dente
AU2014413970B2 (en) * 2014-12-19 2018-07-05 Colgate-Palmolive Company Oral composition for tooth whitening
AR104220A1 (es) * 2015-04-09 2017-07-05 Procter & Gamble Reducción de la aversión al sabor del cpc mediante la reducción de la activación del cpc de los receptores de trpa1, receptores de trpv1, o ambos
CN104887581B (zh) * 2015-06-11 2018-02-23 云南天美天康生物科技有限公司 一种口腔护理组合物及其制备方法
US9889089B2 (en) * 2016-04-04 2018-02-13 Golden Products Llc Dietary supplement non-fluoride toothpaste and methods of making and using same
CA3021255A1 (en) * 2016-04-22 2017-10-26 Innospec Limited A method of treating hair with a composition comprising an alpha-substituted aldehyde
US11485701B2 (en) * 2016-08-23 2022-11-01 Iowa State University Research Foundation, Inc. Insect repellent compounds and compositions, and methods thereof
CA3036897C (en) 2016-10-25 2021-11-16 The Procter & Gamble Company Fibrous structures
CA3037098C (en) 2016-10-25 2023-01-17 The Procter & Gamble Company Differential pillow height fibrous structures
WO2018118141A1 (en) * 2016-12-21 2018-06-28 Colgate-Palmolive Company Oral care compositions
CN106955244B (zh) * 2017-03-03 2019-09-24 广州薇美姿实业有限公司 一种遮盖不良口感的组合物及其在口腔护理产品中的应用
WO2018221620A1 (ja) * 2017-05-31 2018-12-06 ライオン株式会社 歯磨剤組成物
US11389383B2 (en) * 2017-12-20 2022-07-19 Firmenich Sa Oral care compositions
EP3801449A1 (en) * 2018-05-28 2021-04-14 The Procter & Gamble Company Oral care composition with improved deposition efficacy of a cooling sensate agent in the oral cavity
CA3143233A1 (en) * 2019-07-01 2021-01-07 Colgate-Palmolive Company Oral care compositions and methods
JP7660512B2 (ja) 2019-08-30 2025-04-11 アサヒグループホールディングス株式会社 脂肪代謝促進剤
AU2020426517A1 (en) * 2020-01-29 2022-08-18 Rabbit Indústria E Comércio De Produtos De Higiene Pessoal Ltda Oral composition with synergistic association of organic and inorganic components for complete maintenance of oral health, method for obtaining same and uses
JP7559380B2 (ja) 2020-06-29 2024-10-02 ライオン株式会社 口腔用組成物
CN113289020B (zh) * 2021-05-17 2023-04-18 福州大学 蛋白质二硫键异构酶小分子抑制剂及其应用
CN114099524B (zh) * 2021-11-30 2023-06-23 上海芒歌科技有限公司 解辣功效口腔喷雾

Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946725A (en) 1957-03-25 1960-07-26 Procter & Gamble Dentifrice compositions
US3070510A (en) 1959-11-03 1962-12-25 Procter & Gamble Dentifrice containing resinous cleaning agents
US3111127A (en) 1961-06-27 1963-11-19 Brown & Williamson Tobacco Smoking tobacco product and method of making the same
US3535421A (en) 1968-07-11 1970-10-20 Procter & Gamble Oral compositions for calculus retardation
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US3678154A (en) 1968-07-01 1972-07-18 Procter & Gamble Oral compositions for calculus retardation
GB1315626A (en) 1971-02-04 1973-05-02 Wilkinson Sword Ltd Substituted p-menthanes and compositions containing them
US3862307A (en) 1973-04-09 1975-01-21 Procter & Gamble Dentifrices containing a cationic therapeutic agent and improved silica abrasive
US3917613A (en) 1972-08-07 1975-11-04 Francoise Ernestine Lu Humbert Esters of menthol and 2-pyrrolidone or piperidine carboxylic acids
US3959458A (en) 1973-02-09 1976-05-25 The Procter & Gamble Company Oral compositions for calculus retardation
US3991178A (en) 1973-07-13 1976-11-09 Lever Brothers Company Menthyl ester of N-acetylglycine and oral compositions containing same
US4029759A (en) 1972-02-28 1977-06-14 Lever Brothers Company Compositions containing compounds producing a cooling sensation
US4051234A (en) 1975-06-06 1977-09-27 The Procter & Gamble Company Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
US4153679A (en) 1972-04-18 1979-05-08 Wilkinson Sword Limited Acyclic carboxamides having a physiological cooling effect
US4157384A (en) 1972-01-28 1979-06-05 Wilkinson Sword Limited Compositions having a physiological cooling effect
US4178459A (en) 1971-02-04 1979-12-11 Wilkinson Sword Limited N-Substituted paramenthane carboxamides
US4206215A (en) 1976-02-25 1980-06-03 Sterling Drug Inc. Antimicrobial bis-[4-(substituted-amino)-1-pyridinium]alkanes
US4230688A (en) 1972-04-18 1980-10-28 Wilkinson Sword Limited Acyclic carboxamides having a physiological cooling effect
US4340583A (en) 1979-05-23 1982-07-20 J. M. Huber Corporation High fluoride compatibility dentifrice abrasives and compositions
US4459425A (en) 1981-11-20 1984-07-10 Takasago Perfumery Co., Ltd. 3-Levo-Menthoxypropane-1,2-diol
EP0310299A1 (en) 1987-09-28 1989-04-05 The Procter & Gamble Company Beta-amino acid ester derivatives of alcoholic actives having extended duration of activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US5004597A (en) 1987-09-14 1991-04-02 The Procter & Gamble Company Oral compositions comprising stannous flouride and stannous gluconate
US5015466A (en) 1990-06-26 1991-05-14 The Procter & Gamble Company Anticalculus compositions using tartrate-succinates
US5180577A (en) 1990-10-09 1993-01-19 Colgate-Palmolive Stabilized bis biguanide/anionic active ingredient compositions
US5266592A (en) 1991-04-05 1993-11-30 Haarmann & Reimer Gmbh Compositions which have a physiological cooling effect, and active compounds suitable for these compositions
US5281410A (en) 1991-10-23 1994-01-25 The Proctor & Gamble Company Methods of reducing plaque and gingivitis with reduced staining
US5451404A (en) 1992-05-18 1995-09-19 The Procter & Gamble Company Coolant compositions
US5578293A (en) 1994-12-06 1996-11-26 Colgate Palmolive Company Oral compositions containing stabilized stannous compounds having antiplaque and antitartar efficacy
US5589160A (en) 1995-05-02 1996-12-31 The Procter & Gamble Company Dentifrice compositions
US5603920A (en) 1994-09-26 1997-02-18 The Proctor & Gamble Company Dentifrice compositions
US5608119A (en) 1993-09-16 1997-03-04 Takasago International Corporation (2S)-3-[(1R, 2S, 5R)-[5-methyl-2-(1-methylethyl)-cyclohexyl]oxy]-1, 2-propanediol, process for producing the same, and compositions containing the same
US5651958A (en) 1995-05-02 1997-07-29 The Procter & Gamble Company Dentifrice compositions
US5658553A (en) 1995-05-02 1997-08-19 The Procter & Gamble Company Dentifrice compositions
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
US5703123A (en) 1992-08-06 1997-12-30 Haarmann & Reimer Gmbh Method for causing a physiological cooling effect to the skin or mucosa involving the application of carbonic acid esters
US5716601A (en) 1996-03-22 1998-02-10 The Procter & Gamble Company Dentifrice compositions
US5725865A (en) 1995-08-29 1998-03-10 V. Mane Fils S.A. Coolant compositions
US5843466A (en) 1995-08-29 1998-12-01 V. Mane Fils S.A. Coolant compositions
US5874398A (en) * 1997-04-10 1999-02-23 Haarmann & Reimer Gmbh Ethylvanillin isobutyrate
US5977166A (en) 1990-11-06 1999-11-02 Wm. Wrigley Jr. Company Enhanced flavors using menthone ketals
US6365215B1 (en) 2000-11-09 2002-04-02 International Flavors & Fragrances Inc. Oral sensory perception-affecting compositions containing dimethyl sulfoxide, complexes thereof and salts thereof
US6451844B1 (en) 1998-09-18 2002-09-17 Quest International Bv Use of menthyl-2 pyrrolidone-5-carboxylate as an insect repellent
US6592884B2 (en) 2000-05-23 2003-07-15 Nestec S.A. Method of using alpha-keto enamine derivatives as ingredients and products incorporating same
US6884903B2 (en) 2000-07-24 2005-04-26 Aventis Cropscience Gmbh Substituted sulfonylaminomethylbenzoic acid (derivatives) and their preparation
WO2005049553A1 (en) 2003-11-21 2005-06-02 Givaudan Sa N-substituted p-menthane carbosamided
US6956139B2 (en) 2000-02-28 2005-10-18 Takasago International Corporation (1R, 2S, 5R)-3-1-menthoxyalkan-1-OL cooling sensate
WO2006103401A2 (en) 2005-03-29 2006-10-05 Paget, Hugh, Charles, Edward N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use
US7189760B2 (en) 2004-04-02 2007-03-13 Millennium Specialty Chemicals Physiological cooling compositions containing highly purified ethyl ester of N-[[5-methyl-2-(1-methylethyl) cyclohexyl] carbonyl]glycine
US20080050750A1 (en) 2006-07-27 2008-02-28 Redpoint Bio Corporation Screening Assay for Inhibitors of TRPA1 Activation by a Lower Alkyl Phenol
US20080124753A1 (en) 2006-11-15 2008-05-29 Lee Seunghun Paul SpiceMatrix Technology for Taste Compound Identification
WO2008105652A1 (en) * 2007-02-28 2008-09-04 Givaudan Nederland Services B.V. Flavour improving substances
US20080242740A1 (en) 2007-03-29 2008-10-02 Symrise Gmbh & Co. Kg Aroma compositions of alkamides with hesperetin and/or 4-hydroxydihydrochalcones and salts thereof for enhancing sweet sensory impressions
US20080317923A1 (en) 2007-06-19 2008-12-25 Symrise Gmbh & Co. Kg Aroma composition for reducing or suppressing an undesired bitter, astringent impression
US20090004360A1 (en) 2007-05-14 2009-01-01 Cadbury Adams Usa Llc Taste Potentiator Compositions in Oral Delivery Systems
US20090175848A1 (en) 2007-09-17 2009-07-09 Lee S Paul Modulation of the Cooperativity Between the Ion Channels TRPM5 and TRPA1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2440189A1 (fr) * 1978-11-01 1980-05-30 Unilever Nv Produits a usage buccal contenant un germicide cationique de gout amer, avec un arome masquant, et leur preparation
AU4016095A (en) * 1994-11-18 1996-06-17 Procter & Gamble Company, The Oral compositions
US5932192A (en) * 1997-04-23 1999-08-03 Colgate-Palmolive Company Lower astringent two component stannous and potassium salt containing dentifrice
US5900230A (en) * 1997-08-18 1999-05-04 Squigle, Inc. Dental products to treat and prevent periodontal disease
US6169118B1 (en) * 1998-11-12 2001-01-02 Block Drug Company, Inc. Flavor blend for masking unpleasant taste of zinc compounds
US6780443B1 (en) * 2000-02-04 2004-08-24 Takasago International Corporation Sensate composition imparting initial sensation upon contact
JP3497466B2 (ja) * 2000-12-12 2004-02-16 高砂香料工業株式会社 温感組成物
DE60215148T2 (de) * 2001-05-15 2007-08-16 The Procter & Gamble Company, Cincinnati Mundpflegezusammensetzungen
JP2004018431A (ja) * 2002-06-14 2004-01-22 Kiyomitsu Kawasaki 口腔用香料組成物および該香料組成物を含有する口腔組成物
US7851006B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
ES2399059T3 (es) 2005-05-23 2013-03-25 Kraft Foods Global Brands Llc Composiciones potenciadoras del dulzor
US20070036733A1 (en) * 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
EP2203221A2 (en) 2007-10-30 2010-07-07 The Procter & Gamble Chocolate flavored dentifrice with new visuals
US8962057B2 (en) * 2009-04-29 2015-02-24 The Procter & Gamble Company Methods for improving taste and oral care compositions with improved taste

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2946725A (en) 1957-03-25 1960-07-26 Procter & Gamble Dentifrice compositions
US3070510A (en) 1959-11-03 1962-12-25 Procter & Gamble Dentifrice containing resinous cleaning agents
US3111127A (en) 1961-06-27 1963-11-19 Brown & Williamson Tobacco Smoking tobacco product and method of making the same
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US3678154A (en) 1968-07-01 1972-07-18 Procter & Gamble Oral compositions for calculus retardation
US3535421A (en) 1968-07-11 1970-10-20 Procter & Gamble Oral compositions for calculus retardation
US4178459A (en) 1971-02-04 1979-12-11 Wilkinson Sword Limited N-Substituted paramenthane carboxamides
GB1315626A (en) 1971-02-04 1973-05-02 Wilkinson Sword Ltd Substituted p-menthanes and compositions containing them
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
US4157384A (en) 1972-01-28 1979-06-05 Wilkinson Sword Limited Compositions having a physiological cooling effect
US4029759A (en) 1972-02-28 1977-06-14 Lever Brothers Company Compositions containing compounds producing a cooling sensation
US4230688A (en) 1972-04-18 1980-10-28 Wilkinson Sword Limited Acyclic carboxamides having a physiological cooling effect
US4153679A (en) 1972-04-18 1979-05-08 Wilkinson Sword Limited Acyclic carboxamides having a physiological cooling effect
US3917613A (en) 1972-08-07 1975-11-04 Francoise Ernestine Lu Humbert Esters of menthol and 2-pyrrolidone or piperidine carboxylic acids
US3959458A (en) 1973-02-09 1976-05-25 The Procter & Gamble Company Oral compositions for calculus retardation
US3862307A (en) 1973-04-09 1975-01-21 Procter & Gamble Dentifrices containing a cationic therapeutic agent and improved silica abrasive
US3991178A (en) 1973-07-13 1976-11-09 Lever Brothers Company Menthyl ester of N-acetylglycine and oral compositions containing same
US4051234A (en) 1975-06-06 1977-09-27 The Procter & Gamble Company Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies
US4206215A (en) 1976-02-25 1980-06-03 Sterling Drug Inc. Antimicrobial bis-[4-(substituted-amino)-1-pyridinium]alkanes
US4340583A (en) 1979-05-23 1982-07-20 J. M. Huber Corporation High fluoride compatibility dentifrice abrasives and compositions
US4459425A (en) 1981-11-20 1984-07-10 Takasago Perfumery Co., Ltd. 3-Levo-Menthoxypropane-1,2-diol
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US5004597A (en) 1987-09-14 1991-04-02 The Procter & Gamble Company Oral compositions comprising stannous flouride and stannous gluconate
EP0310299A1 (en) 1987-09-28 1989-04-05 The Procter & Gamble Company Beta-amino acid ester derivatives of alcoholic actives having extended duration of activity
US5015466A (en) 1990-06-26 1991-05-14 The Procter & Gamble Company Anticalculus compositions using tartrate-succinates
US5180577A (en) 1990-10-09 1993-01-19 Colgate-Palmolive Stabilized bis biguanide/anionic active ingredient compositions
US5977166A (en) 1990-11-06 1999-11-02 Wm. Wrigley Jr. Company Enhanced flavors using menthone ketals
US5266592A (en) 1991-04-05 1993-11-30 Haarmann & Reimer Gmbh Compositions which have a physiological cooling effect, and active compounds suitable for these compositions
US5281410A (en) 1991-10-23 1994-01-25 The Proctor & Gamble Company Methods of reducing plaque and gingivitis with reduced staining
US5451404A (en) 1992-05-18 1995-09-19 The Procter & Gamble Company Coolant compositions
US5703123A (en) 1992-08-06 1997-12-30 Haarmann & Reimer Gmbh Method for causing a physiological cooling effect to the skin or mucosa involving the application of carbonic acid esters
US5608119A (en) 1993-09-16 1997-03-04 Takasago International Corporation (2S)-3-[(1R, 2S, 5R)-[5-methyl-2-(1-methylethyl)-cyclohexyl]oxy]-1, 2-propanediol, process for producing the same, and compositions containing the same
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
US5603920A (en) 1994-09-26 1997-02-18 The Proctor & Gamble Company Dentifrice compositions
US5578293A (en) 1994-12-06 1996-11-26 Colgate Palmolive Company Oral compositions containing stabilized stannous compounds having antiplaque and antitartar efficacy
US5651958A (en) 1995-05-02 1997-07-29 The Procter & Gamble Company Dentifrice compositions
US5658553A (en) 1995-05-02 1997-08-19 The Procter & Gamble Company Dentifrice compositions
US5589160A (en) 1995-05-02 1996-12-31 The Procter & Gamble Company Dentifrice compositions
US5725865A (en) 1995-08-29 1998-03-10 V. Mane Fils S.A. Coolant compositions
US5843466A (en) 1995-08-29 1998-12-01 V. Mane Fils S.A. Coolant compositions
US5716601A (en) 1996-03-22 1998-02-10 The Procter & Gamble Company Dentifrice compositions
US5874398A (en) * 1997-04-10 1999-02-23 Haarmann & Reimer Gmbh Ethylvanillin isobutyrate
US6451844B1 (en) 1998-09-18 2002-09-17 Quest International Bv Use of menthyl-2 pyrrolidone-5-carboxylate as an insect repellent
US6956139B2 (en) 2000-02-28 2005-10-18 Takasago International Corporation (1R, 2S, 5R)-3-1-menthoxyalkan-1-OL cooling sensate
US6592884B2 (en) 2000-05-23 2003-07-15 Nestec S.A. Method of using alpha-keto enamine derivatives as ingredients and products incorporating same
US6884903B2 (en) 2000-07-24 2005-04-26 Aventis Cropscience Gmbh Substituted sulfonylaminomethylbenzoic acid (derivatives) and their preparation
US6365215B1 (en) 2000-11-09 2002-04-02 International Flavors & Fragrances Inc. Oral sensory perception-affecting compositions containing dimethyl sulfoxide, complexes thereof and salts thereof
WO2005049553A1 (en) 2003-11-21 2005-06-02 Givaudan Sa N-substituted p-menthane carbosamided
US7189760B2 (en) 2004-04-02 2007-03-13 Millennium Specialty Chemicals Physiological cooling compositions containing highly purified ethyl ester of N-[[5-methyl-2-(1-methylethyl) cyclohexyl] carbonyl]glycine
WO2006103401A2 (en) 2005-03-29 2006-10-05 Paget, Hugh, Charles, Edward N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use
US20080050750A1 (en) 2006-07-27 2008-02-28 Redpoint Bio Corporation Screening Assay for Inhibitors of TRPA1 Activation by a Lower Alkyl Phenol
US20080124753A1 (en) 2006-11-15 2008-05-29 Lee Seunghun Paul SpiceMatrix Technology for Taste Compound Identification
WO2008105652A1 (en) * 2007-02-28 2008-09-04 Givaudan Nederland Services B.V. Flavour improving substances
US20080242740A1 (en) 2007-03-29 2008-10-02 Symrise Gmbh & Co. Kg Aroma compositions of alkamides with hesperetin and/or 4-hydroxydihydrochalcones and salts thereof for enhancing sweet sensory impressions
US20090004360A1 (en) 2007-05-14 2009-01-01 Cadbury Adams Usa Llc Taste Potentiator Compositions in Oral Delivery Systems
US20080317923A1 (en) 2007-06-19 2008-12-25 Symrise Gmbh & Co. Kg Aroma composition for reducing or suppressing an undesired bitter, astringent impression
US20090175848A1 (en) 2007-09-17 2009-07-09 Lee S Paul Modulation of the Cooperativity Between the Ion Channels TRPM5 and TRPA1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
H. R. WATSON ET AL., J. SOC. COSMET. CHEM., vol. 29, 1978, pages 185 - 200
HU, HONGZHEN ET AL., NATURE CHEMICAL BIOLOGY, vol. 5, no. 3, 2009, pages 183 - 190
PIER GIOVANNI BARALDI ET AL.: "Transient Receptor Potential Ankyrin 1 (TRPA1) Channel as Emerging Target for Novel Analgesics and Anti-Inflammatory Agents", J. MED. CHEM., SUBMITTED, 15 January 2010 (2010-01-15)
R. ECCLES, J. PHARM. PHARMACOL., vol. 46, 1994, pages 618 - 630
R. EMBERGER, R. HOPP: "Synthesis and Sensory Characterization of Menthol Enantiomers and Their Derivatives for the Use in Nature Identical Peppermint Oils", SPECIALTY CHEMICALS, vol. 7, no. 3, 1987, pages 193 - 201
WEI ET AL., J. PHARM. PHARMACOL., vol. 35, 1983, pages 110 - 112

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015134754A (ja) * 2013-12-19 2015-07-27 花王株式会社 香料前駆体
US10113135B2 (en) 2013-12-19 2018-10-30 Kao Corporation Perfuming method
JP2017008446A (ja) * 2015-06-23 2017-01-12 花王株式会社 液体柔軟剤組成物
WO2017116445A1 (en) 2015-12-30 2017-07-06 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
EP3383502A4 (en) * 2015-12-30 2019-05-15 Colgate-Palmolive Company MOUTHPROOF PRODUCTS AND METHOD FOR THEIR USE AND MANUFACTURE
US10980719B2 (en) 2015-12-30 2021-04-20 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
KR20190107718A (ko) * 2017-03-16 2019-09-20 가부시키가이샤 지씨 치아 표백용 조성물
KR102206349B1 (ko) 2017-03-16 2021-01-22 가부시키가이샤 지씨 치아 표백용 조성물

Also Published As

Publication number Publication date
MX2013003645A (es) 2013-05-22
EP2621462A1 (en) 2013-08-07
PL2621462T3 (pl) 2020-07-27
US20120082628A1 (en) 2012-04-05
US9937115B2 (en) 2018-04-10
EP2621462B1 (en) 2020-02-12
ES2787606T3 (es) 2020-10-16
AU2011308857A1 (en) 2013-05-02
AU2011308857B2 (en) 2015-11-05
MX349338B (es) 2017-07-21
BR112013007295A2 (pt) 2016-06-14
CN103140209A (zh) 2013-06-05
CA2813334A1 (en) 2012-04-05
CA2813334C (en) 2017-03-14
CN103140209B (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
AU2011308857B2 (en) Oral care compositions with improved flavor
EP2854750B1 (en) Trpa1 antagonists for reducing negative sensations caused by hydrogen peroxide
CA2813343A1 (en) Oral care compositions with improved sweetness
US20200297595A1 (en) Oral Care Compositions With An Enhanced Sensory Experience
US10111819B2 (en) Reduction in CPC taste aversion by reducing CPC activation of TRPA1, TPRV1, or both
US9951295B2 (en) Compositions for deposition on biological surfaces

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180047416.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11770264

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/003645

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2813334

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011770264

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011308857

Country of ref document: AU

Date of ref document: 20110929

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013007295

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013007295

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130327